CG
BSTC

Caprock Group’s BioSpecifics Technologies Corp. BSTC Stock Holding History

Caprock Group’s Portfolio BSTC Stock Details BSTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-4,155
Closed -$206K – 481
2017
Q2 		$206K Buy
+4,155
New +$218K 0.05% 379

Other funds holding BSTC

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
ECP
Elk Creek Partners Denver, Colorado $582M AUM 10.23% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
NC
Northpointe Capital Bloomfield Hills, Michigan $258M AUM 1.97% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Caprock Group's BSTC Position: Q3 2017 in Review

Caprock Group sold out of BioSpecifics Technologies Corp. (BSTC) in Q3 2017, closing a stake of 4,155 shares — an estimated $206K sold.

Caprock Group first reported a position in BSTC in Q2 2017 and held it in 1 quarter. The position peaked at $206K in Q2 2017. 87 funds tracked by Wall St. Rank hold BSTC as of Q3 2017.

  • Caprock Group reported no remaining BioSpecifics Technologies Corp. position as of Q3 2017 after selling out during the quarter.
  • Caprock Group sold 4,155 BioSpecifics Technologies Corp. shares in Q3 2017, an estimated $206K.
  • Caprock Group first reported a position in BioSpecifics Technologies Corp. in Q2 2017 and held it in 1 quarter.
  • Caprock Group's BioSpecifics Technologies Corp. position peaked at $206K in Q2 2017.
  • 87 funds tracked by Wall St. Rank held BioSpecifics Technologies Corp. as of Q3 2017.

Based on Caprock Group's 13F filing for Q3 2017, filed 23 Oct 2017.